Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092516 · ClinicalTrials.gov registry record · NA
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
A NA study of Post Acute Sequelae of COVID-19 and Dysexecutive Syndrome, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05092516 is a NA study of Post Acute Sequelae of COVID-19 and Dysexecutive Syndrome that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 182-participant average among 8 other Post Acute Sequelae of COVID-19 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05092516, a NA study of Post Acute Sequelae of COVID-19 and Dysexecutive Syndrome, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.
Conditions Studied
Interventions
- DEVICE Sham tDCS
- DEVICE Active tDCS
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2026-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05092516
The ClinicalTrials.gov registry entry for NCT05092516 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 8 other Post Acute Sequelae of COVID-19 trials with a reported enrollment target (78% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Post Acute Sequelae of COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Sham tDCS is the first listed.
NCT05092516 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05092516 about?
NCT05092516 is a clinical study titled "Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)". The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric current...
What is the current status of trial NCT05092516?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2022-06-07. Estimated completion is 2026-06-15.
What conditions does trial NCT05092516 study?
This clinical trial studies the following conditions: Post Acute Sequelae of COVID-19, Dysexecutive Syndrome.
What interventions are being tested in trial NCT05092516?
The interventions under investigation include: Sham tDCS (DEVICE), Active tDCS (DEVICE).
Who is sponsoring clinical trial NCT05092516?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05092516 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Acute Sequelae of COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autoimmune Intervention Mastery Course Study
RECRUITING · NA
-
Mind Body Intervention for Long COVID-19
RECRUITING · NA
-
Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD)
COMPLETED · NA
-
COVID-19 Outcome Prediction Algorithm
RECRUITING
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
RECRUITING · Phase 1
Explore more on PlainTrial
Post Acute Sequelae of COVID-19
All registered trials for this condition
Dysexecutive Syndrome
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.